Pfizer Inc.
Explore Pfizer Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Pfizer Inc.
Explore Pfizer Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$62.6B
Market Cap
$148.0B
Net Income
$8.0B
Employees
88,000
Pfizer's revenue in 2021 was $81.3 billion. In 2022 it was $100.3 billion — the COVID vaccine and Paxlovid antiviral together added roughly $57 billion in revenue in their peak year. In 2023, as vaccine demand normalized and governments stopped stockpiling antivirals, revenue fell to $58.5 billion. By FY2025 it had recovered to $62.6B. These four data points describe a company whose underlying business is growing, distorted by an extraordinary windfall and its subsequent normalization. Net income of $8.0 billion in 2024 sits against a market capitalization of $148 billion — a price-to-earnings ratio that reflects both the earnings recovery from the 2023 decline and investor uncertainty about the patent cliff ahead. Key drugs in the portfolio face generic competition over the next five to seven years, a structural challenge that every large pharmaceutical company manages through pipeline investment and acquisitions. The $43 billion Seagen acquisition completed in 2023 was the largest deployment of COVID-era capital. Seagen's antibody-drug conjugate technology — engineered molecules that deliver chemotherapy directly to cancer cells — represents a platform Pfizer management believes will generate multiple blockbuster drugs. The financial case requires those drugs to actually reach market and achieve commercial adoption, a process measured in years. Pfizer's founding investment of $2,500 in 1849 grew into the company that produced the first major mRNA vaccine at commercial scale in 2021. The $90,000 equivalent starting capital and the $148 billion current market cap represent 175 years of compounding through exactly the reinvestment-in-discovery cycle that has characterized every major pharmaceutical innovator. The question is whether that cycle continues to generate the next Lipitor, the next Paxlovid — or whether the patent expirations ahead will require the next defining acquisition to maintain the revenue trajectory.
Revenue Trend Analysis
YoY Change
-1.6%
5-Year CAGR
+8.3%
Peak Year
2022
Trend
Mostly Growing
Pfizer Inc. has reported revenue across 6 fiscal years, compounding at +8.3% annually over 5 years. The most recent year saw a 1.6% decline versus the prior year. Revenue peaked in 2022 at $100.3B. Out of 5 reported periods, 3 showed growth and 2 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $62.6B | — | -1.6% |
| FY2024 | $63.6B | $8.0B | +8.7% |
| FY2023 | $58.5B | — | -41.7% |
| FY2022 | $100.3B | — | +23.4% |
| FY2021 | $81.3B | — | +94.0% |
| FY2020 | $41.9B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Pfizer revenue climbed from $41.9 billion in 2020 to $81.3 billion in 2021 and a record $100.3 billion in 2022, driven by Comirnaty COVID vaccine ($37 billion in 2022) and Paxlovid antiviral ($18.9 billion in 2022). Net income peaked at $31.4 billion in 2022. The collapse in vaccination demand and inventory write-downs cut revenue to $58.5 billion in 2023, with the company taking $5.6 billion of Paxlovid inventory and revenue-reversal charges plus $1.2 billion related to lower COVID-19 product sales. Revenue recovered to $63.6 billion in 2024, with COVID products contributing roughly $11 billion combined ($5.4 billion Comirnaty, $5.6 billion Paxlovid). Adjusted earnings per share dropped from $6.58 in 2022 to $1.84 in 2023 before recovering to $3.11 in 2024. The stock fell from a peak above $60 in late 2021 to below $25 by mid-2024, a roughly 60% decline. Market capitalization compressed from $330 billion at the COVID peak to around $148 billion by late 2024. Free cash flow declined from $29.9 billion in 2022 to $9.9 billion in 2023 and recovered to roughly $9 billion in 2024 as working capital normalized.
Pfizer's three largest historical deals were Warner-Lambert in 2000 ($90 billion stock for Lipitor and Adams confectionery, sold to Cadbury in 2002 for $4.2 billion), Pharmacia in 2003 ($60 billion for Celebrex and biotech assets), and Wyeth in 2009 ($68 billion for Prevnar vaccine and consumer health). The 2010s saw mid-sized deals including King Pharmaceuticals in 2011 ($3.6 billion), Hospira in 2015 ($17 billion for injectables and biosimilars), and Medivation in 2016 ($14 billion for Xtandi). The 2020s post-COVID buying spree included Array BioPharma in 2019 ($11.4 billion, oncology), Arena Pharmaceuticals in 2022 ($6.7 billion, etrasimod), Biohaven in 2022 ($11.6 billion, Nurtec migraine), Global Blood Therapeutics in 2022 ($5.4 billion, sickle cell disease), ReViral in 2022 ($525 million, RSV antivirals), and Seagen in 2023 at $43 billion to build oncology leadership. Cumulative deal spend exceeded $400 billion across history. The Seagen acquisition was financed with roughly $31 billion of new debt plus existing cash from COVID profits, lifting Pfizer's leverage to 3.3x EBITDA at close. Two failed mega-deals, AstraZeneca ($118 billion in 2014) and Allergan ($160 billion in 2015), would have been even larger had they succeeded.
Pfizer traded with a market capitalization of approximately $148 billion in late 2024, down from a peak near $330 billion in December 2021 at the height of COVID vaccine demand. Reported 2024 revenue was $63.6 billion (up 7% from $58.5 billion in 2023). Operating income recovered to about $13 billion from $4 billion in 2023, which had been depressed by Paxlovid inventory write-downs. Net income reached $8.0 billion in 2024 versus $2.1 billion in 2023 and $31.4 billion in 2022. Pfizer carries roughly $61 billion of long-term debt after funding the Seagen acquisition, targeting deleveraging to 2.5x EBITDA by 2027. The dividend was $1.68 per share annually in 2024, yielding around 6%, one of the highest in pharmaceuticals. R&D was approximately $10.8 billion in 2024, down from $11.4 billion in 2023 as the company reprioritized programs and discontinued candidates including obesity drug danuglipron. SG&A came in around $14.7 billion. Pfizer announced a multi-year $4 billion cost realignment program through 2024, expanded by $1.5 billion through 2027 plus $1.2 billion of manufacturing optimization announced separately in 2024.
Starboard Value, run by Jeffrey Smith, disclosed a roughly $1 billion stake in Pfizer in October 2024 and pressed for management accountability after the stock dropped roughly 60% from its 2021 peak. Starboard's thesis was that Pfizer mishandled its COVID windfall by spending more than $70 billion on acquisitions including Seagen ($43 billion), Biohaven ($11.6 billion), Arena ($6.7 billion), Global Blood Therapeutics ($5.4 billion), and ReViral ($525 million) without delivering corresponding pipeline value. The activist enlisted former Pfizer CEO Ian Read and former CFO Frank D'Amelio to advise its campaign, an unusual move that signaled internal frustration with current management led by CEO Albert Bourla. Pfizer's board pushed back, while the company accelerated cost-cutting, announced sale of additional Haleon shares (netting roughly $3.3 billion in May 2024), and pulled the obesity drug danuglipron from development in late 2024 after disappointing data. By early 2025 Starboard had not won board seats but had succeeded in forcing visible discipline including reorganization of the commercial oncology business and clearer capital allocation commitments. The episode echoed past activist pressure on Big Pharma, including Trian's stake in DuPont and Pershing Square's earlier campaigns.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Pfizer Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/pfizer/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Pfizer Inc. reported $63B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/pfizer/financials" target="_blank" rel="noopener">CorpDigest — Pfizer Inc. financials</a></div>